Avandia and the Commerical Impact of FDA's Credibilty Gap

Posted by Minerva Novoa at 09/13/07 03:24 PM

GlaxoSmithKline’s diabetes drug Avandia survived a perilous FDA advisory committee review. The real question is whether the industry can survive the damage to FDA’s credibility.

Download the document: http://www.consumersunion.org/pdf/RPMreport0907.pdf PDF